CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 85.24% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
3.4620
4.53%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0460
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023624 %
Charges from full value of position ($-4.49)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023624%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001401 %
Charges from full value of position ($0.27)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001401%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 3.312
Open 3.352
1-Year Change -65.78%
Day's Range 3.352 - 3.552
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
May 2, 2025 3.4620 0.1200 3.59% 3.3420 3.5720 3.3420
May 1, 2025 3.3120 0.1300 4.09% 3.1820 3.3720 3.1020
Apr 30, 2025 3.2420 0.1300 4.18% 3.1120 3.3120 3.0520
Apr 29, 2025 3.1920 0.3600 12.71% 2.8320 3.2420 2.7720
Apr 28, 2025 2.8620 -0.0300 -1.04% 2.8920 2.9220 2.6220
Apr 25, 2025 2.9020 0.0100 0.35% 2.8920 2.9820 2.7820
Apr 24, 2025 2.9520 0.1300 4.61% 2.8220 3.0720 2.8220
Apr 23, 2025 2.8320 -0.1300 -4.39% 2.9620 2.9720 2.7820
Apr 22, 2025 2.9420 0.2100 7.69% 2.7320 3.0020 2.7220
Apr 21, 2025 2.7120 -0.1700 -5.90% 2.8820 2.9920 2.6920
Apr 17, 2025 2.9020 -0.1100 -3.65% 3.0120 3.0120 2.7220
Apr 16, 2025 2.9620 -0.1400 -4.51% 3.1020 3.2220 2.8620
Apr 15, 2025 3.1820 -0.1000 -3.05% 3.2820 3.6120 3.0720
Apr 14, 2025 3.4120 0.0800 2.40% 3.3320 3.5220 3.2220
Apr 11, 2025 3.3820 0.1800 5.62% 3.2020 3.4520 3.2020
Apr 10, 2025 3.3020 -0.2100 -5.98% 3.5120 3.5120 3.1720
Apr 9, 2025 3.5620 0.2600 7.87% 3.3020 3.6520 3.0420
Apr 8, 2025 3.3820 -0.2400 -6.63% 3.6220 3.7520 3.2920
Apr 7, 2025 3.5920 -0.1000 -2.71% 3.6920 3.8520 3.3820
Apr 4, 2025 3.8320 0.0700 1.86% 3.7620 3.9920 3.7320

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Adverum Biotechn Company profile

About Adverum Biotechnologies Inc

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting ocular and rare diseases. It develops gene therapy product candidates. Its ADVM-022, is a clinical-stage gene therapy product candidate developed for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). ADVM-022, is given as a one-time in-office intravitreal (IVT) injection and is designed to reduce the burden of anti-vascular endothelial growth factor (anti-VEGF) injections, optimize patient compliance and improve vision outcomes for patients with wet AMD or DME. It is conducting the OPTIC trial, designed as a multi-center, open-label, Phase I, dose-ranging safety trial of ADVM-022 in patients with wet AMD, who have demonstrated responsiveness to anti-VEGF treatment. It is also conducting the INFINITY trial, a multi-center, Phase II, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of ADVM-022 in patients with DME.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Adverum Biotechnologies Inc revenues increased from $0K to $7.5M. Net loss increased 39% to $111.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing increase of 74% to $37.8M (expense), Research and development -gross increase of 31% to $59.5M (expense).

Industry: Bio Therapeutic Drugs

100 Cardinal Way
REDWOOD CITY
CALIFORNIA 94063
US

People also watch

US100

20,107.00 Price
+2.090% 1D Chg, %
Long position overnight fee -0.0236%
Short position overnight fee 0.0014%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

1,835.36 Price
-0.610% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 1.75

Gold

3,241.23 Price
+0.090% 1D Chg, %
Long position overnight fee -0.0180%
Short position overnight fee 0.0098%
Overnight fee time 21:00 (UTC)
Spread 0.30

BTC/USD

96,101.40 Price
-1.020% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 50.00

Still looking for a broker you can trust?

Join the 720,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading